NEW YORK (GenomeWeb News) – Precision BioSciences today said that the US Patent and Trademark Office is reexamining two patents that have been licensed to Cellectis and that are part of ongoing litigation between the two firms.

The patents — US Nos. 7,214,536 and 6,833,252 — are owned by the Institut Pasteur and the Universite Pierre et Marie Curie and have been licensed to Cellectis. They are among 13 issued US patents that Cellectis is asserting against Precision BioSciences.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The president of France's National Research Agency has resigned, according to Nature News.

A senator wants a "right-to-try" provision in the US Food and Drug Administration funding bill, but an ethicist says at Stat News that it would undermine the role of clinical trials.

In PNAS this week: red algae Porphyra umbicalis genome, deep neural network model for sequencing peptides, and more.

The Guardian's Barbara Ellen has tried out some DNA testing services to see whether they provide valuable information.